Drug & supplement interaction

Limosilactobacillus Reuteri + Entrectinib

Entrectinib brand name: Rozlytrek.

No Known Interaction
Medically reviewed by · Updated July 2026 · Pair last verified Sep 13, 2026
The bottom line No known interaction

We found no known interaction between Limosilactobacillus Reuteri and Entrectinib in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share
Facebook Post Reddit Email
On this page
Interaction report

Limosilactobacillus Reuteri and Entrectinib

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Entrectinib and Limosilactobacillus Reuteri in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Limosilactobacillus Reuteri safety at a glance

Limosilactobacillu... overall Use caution Generally well tolerated in healthy people, but caution is needed in those who are seriously ill or immunocompromised.
Pregnancy Possibly Safe When used orally and appropriately. Read the full pregnancy detail
Breastfeeding Possibly Safe When used orally and appropriately. Although clinical research during lactation is lacking, no safety concerns have been shown in clinical research involving in... Read the full breastfeeding detail

Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center) — the full detail is in the Special populations card below. Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Entrectinib and Limosilactobacillus Reuteri? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
How we checked

Why No Interaction Is Listed for Entrectinib

Interactions in our licensed database are recorded against drug classes, not just single drug names. Entrectinib is filed under 4 classifications — including qt interval-prolonging drugs, hepatotoxic drugs, cytochrome p450 3a4 (cyp3a4) substrates. Limosilactobacillus Reuteri has documented interactions with 1 drug class — the most serious being antibiotic drugs (moderate) — and none of Entrectinib’s classifications are among them.

Classification data comes from our licensed Natural Medicines dataset. A medication can belong to classes beyond those recorded there, so this describes how the check was run — it is not a safety guarantee.

Keep it in perspective

Limosilactobacillus Reuteri Does Interact With Other Medications

Limosilactobacillus Reuteri has 182 moderate known drug interactions in our database — Entrectinib isn’t one of them. If you take anything else, check it against the full list below.

Moderate 182 No known interaction 2,648 (incl. Entrectinib)
Taking anything else?

Check Another of Your Medications Against Limosilactobacillus Reuteri

Covers the 2,830 medications we’ve checked against Limosilactobacillus Reuteri. Pick one to open its full report.

What to actually watch for

No Interaction Found — But Data Suggests Limosilactobacillus Reuteri and Entrectinib May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do. One of them is worth acting on rather than waiting out — marked below.

  • A higher chance of infection Worth acting on Additional detail

    Limosilactobacillus Reuteri

    “Since Limosilactobacillus reuteri preparations contain live and active microorganisms, there is some concern that they might cause pathogenic infection in some patients. Some lactobacilli species have been isolated in some cases of bacteremia, sepsis, splenic abscess, endocarditis, necrotizing fasciitis, pancreatic necrosis, and meningoencephalitis.”

    Limosilactobacillus Reuteri · Natural Medicines adverse-effect record, reported in sepsis.

    1 source cited
    1. 107543. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed

    Entrectinib

    Listed in the ADVERSE REACTIONS section of the FDA label for Entrectinib. Read the label on DailyMed ›

  • Constipation / Diarrhea reported in 4.0% of FDA reports for Entrectinib Additional detail

    Limosilactobacillus Reuteri

    “Orally, taking Limosilactobacillus reuteri alone or in combination with other probiotics may cause gastrointestinal side effects including diarrhea and constipation; however, these events are uncommon.”

    Limosilactobacillus Reuteri · Natural Medicines adverse-effect record, reported in constipation.

    2 sources cited
    1. 90235. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
    2. 107507. Ojetti V, Gigante G, Gabrielli M, et al. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci. 2010;14(3):163-70.

    Entrectinib

    Listed in the ADVERSE REACTIONS section of the FDA label for Entrectinib, and in voluntary FDA adverse-event reports. Read the label on DailyMed ›

Effects for Entrectinib come from the ADVERSE REACTIONS section of its FDA label; effects for Limosilactobacillus Reuteri come from the Natural Medicines adverse-effect record, quoted above. Where a percentage is shown, it is the share of 1,653 voluntary FDA FAERS reports for Entrectinib that mention that effect — a reporting proportion, not an incidence rate and not evidence the drug caused it. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Special populations

Limosilactobacillus Reuteri in Pregnancy & Breastfeeding

Pregnancy Possibly Safe

When used orally and appropriately.

Lactation Possibly Safe

When used orally and appropriately. Although clinical research during lactation is lacking, no safety concerns have been shown in clinical research involving infants up to 3 months of age.

DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.© 2026 Therapeutic Research Center

Everything else you take

See Every Supplement That Interacts With Entrectinib

This page covers Limosilactobacillus Reuteri only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Entrectinib page lists 175 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: Activated Charcoal (major), American Hellebore (major), Arsenic (major), Beer (major) and Cesium (major).

By severity: 11 major · 127 moderate · 37 minor.

From our pharmacist’s overview on the Entrectinib page

“Grapefruit tops my worry list for anyone taking entrectinib (Rozlytrek), a targeted cancer therapy cleared by the liver enzyme CYP3A4. 121 of the 175 supplement ingredients on this page can shift how that enzyme handles the drug.”

Reviewed by 2 · Jul 18, 2026

Open the Entrectinib interaction page

How much people look this up

Where Limosilactobacillus Reuteri and Entrectinib Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Limosilactobacillus Reuteri
Steady interest

#1,133 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Entrectinib
Top half

#861 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Limosilactobacillus Reuteri reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Limosilactobacillus Reuteri and Entrectinib records this page draws on were last updated July 11, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Supplement

About Limosilactobacillus Reuteri

What is Limosilactobacillus Reuteri?

  • Infant colic
  • Diarrhea (including antibiotic-associated)
  • Digestive health
  • Oral and gum health
  • Constipation
  • Immune support

Limosilactobacillus reuteri (formerly Lactobacillus reuteri) is a probiotic bacterium found in the human gut and certain fermented foods. It has the most supportive evidence for reducing crying in breastfed infants with colic and for some types of diarrhea, while many other uses remain unproven. It is generally well tolerated in healthy people, but people who are very ill or immunocompromised should talk to a doctor first.

Limosilactobacillus reuteri · Lactobacillaceae · Live bacterial cells (probiotic strains) · Chewable tablets, drops/oils, capsules, powders, fortified foods and yogurt

An interaction check asks whether these two react with each other — it does not ask whether Limosilactobacillus Reuteri is a good idea for someone in your situation. Here is what our Limosilactobacillus Reuteri record says about it on its own.

Limosilactobacillus Reuteri: dosing

There is no single official dose for L. reuteri. Do not assume a higher dose is better.

From our Limosilactobacillus Reuteri monograph — the full record covers uses, side effects and every documented interaction.

Read the full Limosilactobacillus Reuteri monograph & all interactions
Medication

About Entrectinib

What Is Entrectinib Used For?

Brand name: Rozlytrek

Rozlytrek is used to treat adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) — a type of lung cancer where the ROS1 gene is rearranged — as confirmed by an FDA-approved test.

Rozlytrek is also approved for adult and pediatric patients older than 1 month with solid tumors that have an NTRK gene fusion (a specific genetic alteration), detected by an FDA-approved test, that have spread or cannot be removed without causing serious harm, and have worsened after prior treatment or have no good treatment alternatives. This NTRK indication was granted accelerated approval based on tumor response rates; continued approval may depend on results from confirmatory trials.

Most-Reported Side Effects for Entrectinib

From FAERS, the FDA’s public side-effect reporting system (1,653 reports, all brands). Reports are voluntary and are not proof the drug caused the effect.

Dizziness 150 reports
Disease progression 117 reports
Taste disorder 71 reports
Constipation 66 reports
Blood creatinine increased 62 reports
See full Entrectinib drug information
Keep checking

Other Drugs & Limosilactobacillus Reuteri

Browse every other medication we’ve checked against Limosilactobacillus Reuteri — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
182Moderate
0Minor
2,647No known interaction
182 Moderate 2,647 No interaction
Moderate

182 interactions

Showing 60 of 182 moderate interactions — see all 182 on the Limosilactobacillus Reuteri page.

No interaction 2,647 drugs checked — show the list

We also checked Limosilactobacillus Reuteri against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,647 medications checked with no known interaction — see the full Limosilactobacillus Reuteri list.

See the full Limosilactobacillus Reuteri interactions page
See every supplement checked against Entrectinib, ranked by severity
Evidence & sources

Limosilactobacillus Reuteri References

The 14 references that drive our Limosilactobacillus Reuteri monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010;126:e526-33.
  3. Savino F, Pelle E, Palumeri E, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007;119:e124-30.
  4. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
  5. Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, Koren G.Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 2015;166(1):74-8. PubMed
  6. Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, Ballardini E, Bisceglia M, Cinquetti M, Brazzoduro E, Del Vecchio A, Tafuri S, Francavilla R. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional const
  7. Oncel MY, Sari FN, Arayici S, Guzoglu N, Erdeve O, Uras N, Oguz SS, Dilmen U. Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2014;99(2
  8. Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A,Barr RG, Wake M. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014 1;348:g2107. PubMed
  9. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind,placebo-controlled trial. J Pediatr. 2013;162(2):257-62. PubMed
  10. Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020;127(2):275-284. PubMed
  11. Ojetti V, Gigante G, Gabrielli M, et al. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci. 2010;14(3):163-70.
  12. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  13. Sheyholislami H, Connor KL. Are probiotics and prebiotics safe for use during pregnancy and lactation? A systematic review and meta-analysis. Nutrients. 2021;13(7):2382. PubMed
  14. Yefet E, Colodner R, Strauss M, Gam Ze Letova Y, Nachum Z. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm la

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Limosilactobacillus Reuteri and Entrectinib Together: Common Questions

Is it safe to take Limosilactobacillus Reuteri with Entrectinib?
We do not list a known interaction between Limosilactobacillus Reuteri and Entrectinib. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Limosilactobacillus Reuteri and Entrectinib have any of the same side effects?
Yes — our sources link each of them separately to 3 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
How was the Limosilactobacillus Reuteri and Entrectinib combination checked?
Interactions in our licensed database are recorded against drug classes. Entrectinib is filed under 4 classifications, and Limosilactobacillus Reuteri has documented interactions with 1 drug class — none of Entrectinib's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.
Does Limosilactobacillus Reuteri interact with any other medications?
Yes. Limosilactobacillus Reuteri has 182 documented drug interactions in our database — Entrectinib is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.
Does Entrectinib interact with any supplements?
Yes. Entrectinib has documented interactions with 175 supplements in our database — Limosilactobacillus Reuteri is not one of them. The Entrectinib interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Limosilactobacillus Reuteri monograph Uses, safety profile, and every drug interaction in one place Entrectinib drug information The full plain-English guide to this medication Entrectinib supplement interactions Every supplement checked against Entrectinib, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 14 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Entrectinib and Limosilactobacillus Reuteri?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.